Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) has shared an update.
ResMed Inc. has filed its Form 10-Q for the quarter ended December 31, 2025, confirming that it remains a large accelerated filer in full compliance with U.S. Securities and Exchange Commission reporting requirements and electronic data submission standards. The quarterly report includes unaudited condensed consolidated financial statements, management’s discussion and analysis, risk factor disclosures, and other required information, underscoring the company’s ongoing transparency to investors and regulators and providing an updated view of its financial condition, capital structure, and governance status, including share count and treasury share levels.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. is a Delaware-incorporated medical technology company listed on the New York Stock Exchange under the ticker RMD. Headquartered in San Diego, California, it develops and sells devices and software solutions for the diagnosis, treatment, and management of sleep-disordered breathing and other chronic respiratory conditions, serving patients, healthcare providers, and payers in global healthcare markets.
Average Trading Volume: 1,055,786
Technical Sentiment Signal: Buy
Current Market Cap: A$54.17B
Find detailed analytics on RMD stock on TipRanks’ Stock Analysis page.